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Abstract
Background: Definite Alzheimer’s disease (AD) requires neuropathological confirmation. Single-photon emission
computed tomography (SPECT) may enhance diagnostic accuracy, but due to restricted sensitivity and specificity,
the role of SPECT is largely limited with regard to this purpose.
Methods: We propose a new method of SPECT data analysis. The method is based on a combination of parietal
lobe selection (as regions-of-interest (ROI)), 3D fuzzy edge detection, and 3D watershed transformation. We applied
the algorithm to three-dimensional SPECT images of human brains and compared the number of watershed
regions inside the ROI between AD patients and controls. The Student’s two-sample t-test was used for testing
domain number equity in both groups.
Results: AD patients had a significantly reduced number of watershed regions compared to controls (p < 0.01). A
sensitivity of 94.1% and specificity of 80% was obtained with a threshold value of 57.11 for the watershed domain
number. The narrowing of the SPECT analysis to parietal regions leads to a substantial increase in both sensitivity
and specificity.
Conclusions: Our non-invasive, relatively low-cost, and easy method can contribute to a more precise diagnosis of
AD.
Background
Alzheimer’s disease (AD) is the most common neurode-
generative dementia. Diagnostic criteria are based
mainly on clinically altered cognition. Early diagnosis of
AD is crucial for maximizing treatment benefits. Neuro-
imaging may be helpful in increasing diagnostic preci-
sion, but correlations between localized atrophy, mainly
in the temporal regions, on MRIs, and AD pathology
are still controversial, and promising new techniques
like PET amyloid imaging are not in routine use. Low
beta-amyloid and elevated tau protein levels in cere-
brospinal fluid have been correlated with AD at a sensi-
tivity of 85-94% and a specificity of 83-100% [1].
However, other studies have not been able to confirm
these results and widespread consensus is lacking
regarding its utility in everyday practice [2].
Single photon emission computerized tomography
(SPECT) is a widely used diagnostic method based on
analysis of regional cerebral blood flow (rCBF); with
restricted rCBF considered to reflect hypometabolism
and consequently hypofunction. Typical SPECT AD
patterns show reduced rCBF in both temporal and par-
ietal regions, and, in a recent review, were capable of
distinguishing AD from healthy controls (sensitivity =
65% - 71%; specificity = 79%) [3]. SPECT studies with
autopsy-confirmed diagnoses reported sensitivities of
86 to 95% and specificities of 42 to 73% [4,5]. Since
“raw” data needs further treatment, final results from
SPECT investigations are, at least partly, operator-
dependent and both specificity and sensitivity vary
among centers. Because of its low sensitivity and speci-
ficity, routine use of SPECT is not recommended for
diagnostic purposes [6].
Currently, new methods for signal processing and
supervised learning have demonstrated the potential of
computer aided diagnostic systems [7,8].
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ing interest in the field. The superiority of 3-dimen-
sional stereotactic surface projection analysis (3D-SSP)
over visual inspection for differentiating patients with
very early AD from control subjects using brain perfu-
sion SPECT has been reported [9]. The authors found
that 3D-SSP had an accuracy of 86.2% for differentiating
patients with AD from control subjects when analyzing
the posterior cingulate gyri and precunei. In contrast,
visual inspection only had an accuracy of about 74.0%.
Voxel-based analysis (using specific voxel-based Z score
maps) may be helpful in differentiating AD from vascu-
lar dementia and non-demented patients using a
method which is not influenced by inter-observer differ-
ences among radiologists [10]. These procedures, how-
ever, necessitate special software applications and are
not routinely used in many countries.
Nevertheless, reasonable financial costs and the possi-
bility of using SPECT repetitively for monitoring disease
progression, offer arguments for routine use of SPECT,
assuming that specificity and sensitivity can be increased
through improved data processing.
The aim of our study was to develop a procedure with
at least comparable accuracy to the results of visual
inspection in differentiating AD patients from controls
and at the same time avoid the need for special addi-
tional equipment.
Methods
Our study is based on a post hoc (retrospective) analysis of
raw SPECT data, acquired between 2003 and 2005. The
data were analyzed with respect for patient privacy and
the protocol was approved by the local Ethics Committee.
We enrolled SPECT data from 17 adult patients with
definite Alzheimer’s disease confirmed by autopsy, as
defined by NIA-Reagan Institute criteria as well as the
Consortium to Establish a Registry for Alzheimer’sd i s -
ease criteria.
We routinely perform SPECT in patients with cogni-
tive impairment as a routine diagnostic procedure.
Therefore, in our setting, the data from SPECT scans
and the confirmation of clinical diagnosis of AD were
very timely (within a few weeks). All patients included
in the study were diagnosed with mild to moderate AD
(later confirmed by autopsy) according to NINCDS-
ADRDA and DSM-IV criteria; additionally all patients
were diagnosed with dementia.
Control cases included 10 patients with amyotrophic
lateral sclerosis (ALS), without signs or complaints of
cognitive dysfunction, who underwent SPECT and a
detailed cognitive evaluation as part of a previously pub-
lished research protocol [11].
SPECT studies were performed using a standardized
protocol, which started 40 minutes after injection with
740 MBq 99mTcHMPAO (hexamethylpropyleneamine-
oxime labeled with 99mTechnetium) and used a dual-
head gamma camera (DST-XL SOPHA with LEHR
collimator). We used filtered back projection (FBP) for
image reconstruction. No correction for attenuation
was made.
We prepared 3D SPECT brain scans in six consecutive
operations: (i) image smoothing, (ii) normalization, (iii)
background elimination, (iv) fuzzy edge detection, (v)
watershed segmentation, and (vi) region counting.
Image smoothing (i), used a traditional method of
noise suppression and was performed with a Gaussian
3D filter with radius as the first parameter.
The second step was oriented toward image intensity
normalization (ii) in an interval (0, 1), where unit inten-
sity corresponded to maximum brain activity.
Background elimination (iii) was the next image-pro-
cessing step. The normalized intensity was compared
with a threshold value as the second parameter of data
processing. Positive differences were passed while nega-
tive ones were set to zero.
The fourth step was fuzzy edge detection (iv) based on
Lukasiewicz BL-algebra [12]. Every voxel of the previous
3D image (after step iii) has 6 neighboring voxels; the
fuzzy edge intensity (for a given voxel) was defined as
the aggregate fuzzy non-equivalence between the voxel
and its neighbors. The fuzzy equivalence of two voxel
intensities was realized as a bi-residuum in Lukasiewicz
BL-algebra. Bi-residuum reaches its unit maximum
when the intensities are equal and the value falls to zero
w h e nt h e ya r eo p p o s i t e .T h ef u z z yn o n - e q u i v a l e n c ei s
only a fuzzy negation of equivalence as a complement to
the unit value. The fuzzy aggregation of six pairwise
non-equivalences was performed via a fuzzy “OR” opera-
tor as the maximum function. Applying this procedure
to every voxel and its neighbors, we obtain a 3D image
of fuzzy edges (iv), which depicted structures with maxi-
mum morphological gradients of brain activity.
Edge contours with high intensity can help in image
decomposition based on brain activity. The process of seg-
mentation was automated using a standard 3D watershed
transform (v) and constituted step five. The watershed
method [13] is a tool for the digital image segmentation,
which is based on the study of local minima and their
basins of attraction. Watershed shapes in 3D consists of
points where two basins of attraction are at least in their
neighborhood. Sub-results of this procedure are demon-
strated in Figure 1 for a central slice of the whole SPECT
image of typical AD and control brains. The resulting 3D
image of a parietal ROI was labeled to demarcate the
regions and watershed borderlines (Figures 2, 3).
The last image processing step (vi) counts the total
number of separated 3D regions into regions-of-interest
(ROIs) centered in the left and right parietal lobes.
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Page 2 of 7All statistical calculations were performed using
Matlab Statistical Toolbox from MathWorks Inc.
Statistical characteristics were evaluated as point
estimates together with 95% confidence intervals.
The null hypothesis of the mean value equity was
tested using the two-sample Student’st - t e s t .D u et o
the relatively small groups of AD patients and con-
trols, the ‘leave-one-out’ method [14] of cross-valida-
tion was used to obtain mean values of processing
parameters and their standard deviations. Finally, the
null hypothesis of the mean value equity was tested
using the two-sample Student’s t-test and the sensi-
tivity and specificity of proposed method were
estimated.
Results
The study included 17 adult patients, where definite Alz-
heimer’s disease was confirmed by autopsy using the
NIA-Reagan Institute criteria (neocortical tangles score
Braak V-VI), as well as the Consortium to Establish a
Registry for Alzheimer’s Disease criteria (CERAD plaque
score frequent), and confirmed using specific monoclonal
Figure 1 Processing steps for typical AD patients (left) and
controls (right): original SPECT (1st - above), smoothing and
normalization (2nd), thresholding (3rd), fuzzy edge detection
(4th), watershed (5th - bottom).
Figure 2 Final 3D watershed in a typical AD patient with 40
spatial regions (central slice).
Figure 3 Final 3D watershed in a typical control with 70 spatial
regions (central slice).
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Page 3 of 7antibodies against hyperphosphorylated tau protein and
amyloid beta peptide. Basic patient characteristics are
summarized in Tables 1, 2.
The 3D SPECT scans of 17 AD patients and 10 con-
trols were analyzed as 3D matrices of 128×128×128 vox-
els using the described method with left and right
parietal lobe ROIs having individual sizes of 22×29×3
voxels. Basic characteristics such as gender (F/M), age,
Onset-Diagnosis, Diagnosis-Death, MMSE and the
Braak stage are summarized in Tables 1, 2. The cross-
validation using the ‘leave-one-out’ method had two
main results.
The mean values of processing parameters and their
standard deviations were estimated. The optimum radius
of Gaussian filtering was 0.8997 ± 0.0637, the threshold
value was 0.2761 ± 0.0511 and the critical number of
regions was 57.11 ± 0.32. There were 15 true positive
cases and 8 true negative cases after cross-validation.
Adequate sensitivity was 88.2% and the specificity
reached 80.0%.
The mean values of parameters from cross-validation
were used for the final statistical testing using the two-
sided two-sample t-test. Results of posterior statistical
analysis are presented in Table 3 and Figure 4 as the
number of watershed regions in the ROIs.
SPECT data were recorded by one investigator (M.B.)
while statistical analysis was performed separately two
others (T.B., J.K.) anonymously without any information
about the patients.
The testing criterion value was t = 6.187 and the
probability value was p =3 . 8 × 1 0
-7 ( i . e .p<0 . 0 1 ) ,w h i c h
means significantly fewer numbers of watershed regions
in the AD group compared to controls. The optimum
Table 1 Demographic data of patients and controls
Patient Gender Age (years) MMSE Braak stage Comorbidity
1 M 78 23 VI arterial hypertension
2 F 78 17 VI alcohol abuse 10 years earlier
3 F 57 25 V asthma, glaucoma
4 F 79 20 VI arterial hypertension, coronary by-pass
5 M 74 19 VI NA
6 M 76 20 VI hypertension, minor stroke, diabetes, atrial fibrillation
7 F 83 10 VI NA
8 F 83 20 VI arterial hypertension
9 M 68 20 VI NA
10 M 84 18 VI NA
11 M 83 16 V arterial hypertension, diabetes, myocardial infarction, hyperlipidemia
12 M 80 18 VI arterial hypertension, subarachnoidal hemorrhage 30 years earlier
13 M 81 20 VI NA
14 M 80 21 V prostatic hypertrophy
15 F 86 16 VI ischemic heart disease, diabetes
16 F 80 15 V hypertension, atrial fibrillation
17 F 87 20 V hypertension
Table 2 Basic statistical characteristics of patients and
controls
Group Characteristics Mean SD Minimum Maximum
AD F/M 8/9
Age (years) 78.5 7.2 56 87
Duration onset-diagnosis
(months)
43 19 12 85
Duration diagnosis-death
(months)
19 13 1 50
MMSE 18.7 3.4 10 25
Control F/M 3/7
Age (years) 55.9 7.6 39 70
MMSE 30 0 30 30
AD: Alzheimer’s disease
MMSE: Mini Mental State Examination
F: female M: male subjects
NA: not applicable
Duration onset-diagnosis: time span from manifestation of first AD signs to
clinical diagnosis confirmation
Duration diagnosis-death: time span from clinical diagnosis of AD to death
Table 3 Number of watershed regions for AD and
controls
Characteristics AD patients Value [95%
CI]
Controls Value [95%
CI]
Mean 41.4 [33.7, 47.9] 68.1 [59.4, 76.8]
Std. deviation 9.9 [6.7, 17.9] 12.1 [8.3, 22.1]
Sensitivity (%) 94.1 [59.6, 98.3] NA
Specificity (%) NA 80.0 [44.4, 97.5]
NA: not applicable
CI: confidence interval
AD: Alzheimer’s disease
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Page 4 of 7threshold for watershed regions was set to 57; the num-
ber of true positive cases was TP =1 6a n dt h en u m b e r
of true negative cases was TN = 8. Thus, the method
based on fuzzy edge detection and watershed transform
reached a sensitivity of 94.1% and a specificity of 80.0%
for AD patients and controls.
Discussion
A Dd i a g n o s i si sb a s e dm a i n l yon cognitive evaluation
and a definite diagnosis requires neuropathological find-
ings of beta amyloid deposits and neurofibrillary tangles.
AD is essentially a disease of the elderly and most
patients have co-morbidities that may affect cognition.
It is therefore important to emphasize that all our
patients had neuropathologically proven “pure” Alzhei-
mer’s disease. In our retrospective study, we excluded
all patients with vascular encephalopathy and other neu-
rodegenerative brain disease. We also considered several
co-morbidities in the patients selected to our study
( l i s t e di nT a b l e1 )b u tt h e s ew e r ea s s e s s e da sn o n - r e l e -
vant in terms of their influence on the patient’sc o g n i -
tive performance.
Selection of controls involved two principal conditions:
first, control cases had to have normal cognitive status
and second, SPECT data needed to be available. Given
the fact that SPECT utilizes a radioactive marker, it
would be difficult to propose such an examination for
healthy volunteers. We used post hoc data from an estab-
lished register, which required taking into account that
our controls might be younger than the AD patients
(Table 1, 2) and could constitute a limitation of the study.
Finally, we decided to use data from 10 patients with
amyotrophic lateral sclerosis (ALS) as controls. The
patients were without noticeable co-morbidities, and
had been assessed as part of a previously published
study [11]. At the time of SPECT scanning, the cogni-
tive status of the controls was normal and patients had
no subjective memory and/or cognitive complaints. We
considered them as cognitively normal subjects. Five
control patients died before the end of the study and
selected autopsies showed no significant AD related
pathology.
In order to avoid possible bias, SPECT data acquisi-
tion and diagnostic evaluation were strictly separated
from SPECT data analysis. The investigators (TB, JK)
involved in SPECT data treatment were blinded and did
not have access to any clinical and/or imaging details
about the patients.
We propose a new method of SPECT image proces-
sing that could enhance the accuracy of an AD diagno-
sis. We developed a new approach for treating ‘raw’
SPECT data. The combination of digital filtering, fuzzy
edge detection and watershed method facilitates detec-
tion of hypo-perfusion in a smaller number of localized
segments.
Respecting the typical temporo-parietal SPECT pattern
of AD, we hypothesized that critical differences between
AD patients and controls could be found in the parietal
regions. Focusing SPECT analysis on the parietal regions
substantially increases both sensitivity and specificity,
and approaches the 80% levels recommended by the
Reagan Biomarker Working Group [15].
Figure 4 Box-plot of watershed region number in AD and controls (CN).
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cingulate is also significantly decreased. However, it is
difficult to distinguish a slight decrease in rCBF during
early AD by visual inspection [16]. Moreover, according
to a longitudinal SPECT study [17], decreases in rCBF
adjusted for relative flow distribution, by normalization
of global cerebral blood flow in the posterior cingulate
gyrus and precuneus, became ambiguous as the disease
progressed.
As demonstrated in Figure 1, the spatial resolution of
our procedure is limited, therefore, and respecting the
cited arguments, we decided to analyze ‘traditionally
used’ parietal regions. This decision was supported by a
recent study [18] that described a significant correlation
between tau or phospho-tau concentrations in cere-
brospinal fluid and perfusion in the left parietal cortex
in AD patients.
In our study, the total number of regions was the only
criterion for patient classification. The novelty and effi-
ciency of our method is based on a combination of a
fuzzy edge detector, watershed transform, and orienta-
tion toward activity separation of parietal lobe domains;
other operations were necessary to reduce sensitivity to
noise and artifacts.
Conclusions
SPECT data can be easily manipulated using available
software; underscoring that extra software and/or man-
ual corrections of raw SPECT data is not required;
therefore, our method can be easily used by clinicians.
Additionally, it offers earlier and more precise AD diag-
noses with the associated patient benefits, and it can be
done without significantly increased costs.
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